View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 12, 2022

NIAID initiates Phase I trial of Moderna’s Nipah virus vaccine

The trial will analyse mRNA-1215’s safety, tolerability and potential to induce an immune response in 40 adults.

The National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) has initiated a Phase I clinical trial of Moderna’s experimental vaccine, mRNA-1215, for preventing Nipah virus infection. 

Moderna manufactured the vaccine, which was developed in partnership with Vaccine Research Center of NIAID. 

The vaccine is based on a messenger ribonucleic acid (mRNA) platform, a technology utilised in various Covid-19 vaccines that are currently approved. 

Sponsored by NIAID, the trial is being carried out at the NIH Clinical Center in Bethesda, Maryland, US.

The dose-escalation trial will analyse mRNA-1215’s safety, tolerability and potential to induce an immune response in 40 healthy adult subjects aged 18 to 60 years. 

It will have four groups enrolling 10 subjects each and they will be given two doses of the vaccine through injection in the shoulder muscle at a gap of four or 12 weeks. 

Subjects in group one will be given two 25mcg vaccine doses while groups two and three will receive two 50mcg and 100mcg vaccine doses, respectively, four weeks apart. 

As per the interim assessment data from these groups, the vaccine dose for the fourth group of subjects will be determined. 

The NIH noted that the fourth group will be given two vaccine doses at a gap of 12 weeks. 

Clinical observation and blood collection will be carried out in trial subjects at specified times throughout the trial and monitored till 52 weeks following administration of last vaccine dose.

NIAID director Anthony Fauci said: “Nipah virus poses a considerable pandemic threat because it mutates relatively easily, causes disease in a wide range of mammals, can transmit from person-to-person, and kills a large percentage of the people it infects.”

“The need for a preventive Nipah virus vaccine is significant.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena